Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211419 · ClinicalTrials.gov registry record · Phase 1
Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)
A Phase 1 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00211419: Completed Phase 1 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
NCT00211419 is a Phase 1 study that has completed, run by Manhattan Eye, Ear & Throat Hospital. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00211419, a Phase 1 study, has completed, sponsored by Manhattan Eye, Ear & Throat Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
The purpose of this study is to evaluate the safety of combining juxtasclerally administered anecortave acetate 15 mg with triamcinolone acetate 4 mg administered intravitreally following photodynamic therapy with verteporfin for the treatment of exudative age-related macular degeneration (AMD).
Interventions
- PROCEDURE Photodynamic Therapy with Verteporfin
- DRUG Anecortave Acetate 15 mg
- DRUG Triamcinolone Acetate 4 mg
- PROCEDURE Thermal Laser
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
What the finished NCT00211419 record still lists
NCT00211419 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which Photodynamic Therapy with Verteporfin is the first listed.
NCT00211419 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00211419 about?
NCT00211419 is a clinical study titled "Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)". The purpose of this study is to evaluate the safety of combining juxtasclerally administered anecortave acetate 15 mg with triamcinolone acetate 4 mg administered intravitreally following photodynamic therapy with verteporfin for the treatment of exudative age-related macular degeneration (AMD).
What is the current status of trial NCT00211419?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00211419?
The interventions under investigation include: Photodynamic Therapy with Verteporfin (PROCEDURE), Anecortave Acetate 15 mg (DRUG), Triamcinolone Acetate 4 mg (DRUG), Thermal Laser (PROCEDURE).
Who is sponsoring clinical trial NCT00211419?
This trial is sponsored by Manhattan Eye, Ear & Throat Hospital, which has 14 total clinical trials registered on ClinicalTrials.gov.